Successful treatment of acquired factor VIII inhibitors with cyclosporin
نویسندگان
چکیده
منابع مشابه
Rituximab in the treatment of acquired factor VIII inhibitors.
Autoantibodies against factor VIII (FVIII) are rare but can cause life-threatening bleeding requiring costly factor replacement and prolonged immunosuppression. We report 4 consecutively treated patients whose acquired FVIII inhibitors responded rapidly to immunosuppressive regimens that included rituximab, a monoclonal antibody against CD20(+) B cells. Three patients had spontaneously occurrin...
متن کاملSuccessful elimination of factor VIII inhibitor using cyclosporin A.
Acquired Factor VIII (FVIII) deficiency is an uncommon but sometimes catastrophic autoimmune condition for which standard immune suppression, such as steroid or immunoglobulin infusion, is often insufficient to induce long-term remission (Dykes et al, 2001). A number of second-line therapies, such as cyclophosphamide, azathioprine and vincristine, have been used with varying success (Morrison &...
متن کاملHow I treat acquired Factor VIII inhibitors
Acquired hemophilia A is a rare bleeding diathesis caused by autoantibodies directed against clotting factor VIII and associated with an increased morbidity and mortality. This autoimmune disorder most commonly occurs in the elderly. Although it may be associated with several underlying pathologies, up to 50% of reported cases remain idiopathic. In contrast with congenital hemophilia, which is ...
متن کاملAcquired Factor VIII Inhibitors: Three Cases
UNLABELLED Acquired hemophilia A is a rare, but devastating bleeding disorder caused by spontaneous development of autoantibodies directed against coagulation factor VIII. In 40%-50% of patients it is associated with such conditions as the postpartum period, malignancy, use of medications, and autoimmune diseases; however, its cause is unknown in most cases. Acquired hemophilia A should be susp...
متن کاملSuccessful long-time treatment with mycophenolate-mofetil in a child with acquired factor VIII inhibitor.
UNLABELLED Here, we report about a boy (age: 18 years) who developed an acquired factor VIII inhibitor at the age of 9 years. He presented with bleeding in his right ankle, multiple haematomas and a high-titer factor VIII type II inhibitor (400 BU). THERAPY He received treatment with MMF (CellCept®), dexamethasone-immunoglobulin pulses, and rituximab together with high dose FVIII (Hannover pr...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: American Journal of Hematology
سال: 1998
ISSN: 0361-8609,1096-8652
DOI: 10.1002/(sici)1096-8652(199801)57:1<87::aid-ajh17>3.3.co;2-y